ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT07098364
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-27Est. Completion: 2030-10-04
Enrollment target: 33 participants Locations- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Other microbiome trials you might be interested in
Non-hodgkin Lymphoma
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell l…
Palo Alto, United StatesEst. completion Nov 2028
Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as init…
Duarte, United StatesEst. completion Jul 26, 2022
Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting …
Tucson, United StatesEst. completion Jun 2027